Want to see AU:EBR full AI Analyst Report?
Top Page
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
(Sydney:EBR)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.30
â–Ľ(-1.33% Downside)
Action:Reiterated
Date:08/19/26
The score is primarily held back by heavy ongoing losses and substantial cash burn despite improving revenue traction. Technicals add additional pressure given the clear downtrend and negative MACD. Valuation is difficult to support with a negative P/E and no dividend yield information.
Positive Factors
Commercial adoption is accelerating
Rapid revenue expansion, increasing implant volumes, hospital contracts and physician training indicate that WiSE is progressing from limited launch toward repeatable commercial adoption in cardiac resynchronization therapy.
Negative Factors
Heavy cash burn creates funding dependence
The company is not yet self-funding: operating and free cash flow remain deeply negative despite revenue growth. Continued spending on commercialization and development may require further external capital before revenue reaches breakeven.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial adoption is accelerating
Rapid revenue expansion, increasing implant volumes, hospital contracts and physician training indicate that WiSE is progressing from limited launch toward repeatable commercial adoption in cardiac resynchronization therapy.
Read all positive factors
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (EBR) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$222.23M
Dividend YieldN/A
Average Volume (3M)694.25K
Price to Earnings (P/E)―
Beta (1Y)1.09
Revenue Growth3420.67%
EPS Growth27.04%
CountryAU
Employees135
SectorGeneral
Sector StrengthN/A
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.10
Shares Outstanding845,410,900
10 Day Avg. Volume604,410
30 Day Avg. Volume694,249
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)9.73
Price to Sales (P/S)148.94
P/FCF Ratio-4.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.49Price Target Upside395.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.33
Revenue Forecast (FY)AU$14.67M
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Business Overview & Revenue Model
Company Description
EBR Systems, Inc. is a company focused on creating implantable medical devices that employ wireless technology for tissue stimulation. Their flagship product is the WiSE cardiac resynchronization therapy system, which utilizes a unique wireless me...
How the Company Makes Money
null...
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.38M | 1.67M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 925.70K | 507.09K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -55.70M | -47.28M | -37.73M | -24.66M | -23.62M | ― |
| Net Income | -60.42M | -50.46M | -20.17M | -35.04M | -33.09M | ― |
Balance Sheet | ||||||
| Total Assets | 138.61M | 97.29M | 73.56M | 78.90M | 71.68M | 85.42M |
| Cash, Cash Equivalents and Short-Term Investments | 85.90M | 53.22M | 60.66M | 72.32M | 63.53M | 78.24M |
| Total Debt | 59.65M | 58.63M | 41.40M | 41.59M | 21.59M | 4.81M |
| Total Liabilities | 69.79M | 71.69M | 49.20M | 47.84M | 27.73M | 9.53M |
| Stockholders Equity | 68.83M | 25.61M | 24.36M | 31.06M | 43.95M | 75.90M |
Cash Flow | ||||||
| Free Cash Flow | -74.16M | -58.86M | -41.50M | -33.05M | -31.09M | -934.16K |
| Operating Cash Flow | -65.35M | -55.05M | -41.23M | -32.70M | -30.36M | -22.15K |
| Investing Cash Flow | 3.68M | 8.11M | 1.11M | -8.64M | -49.35M | -906.81K |
| Financing Cash Flow | 74.89M | 48.46M | 32.48M | 40.47M | 17.01M | 95.76M |
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Technical Analysis
Negative
0.30
Price Trends
0.33
Negative
0.42
Negative
0.61
Negative
Market Momentum
-0.01
Negative
43.11
Neutral
63.70
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EBR, the sentiment is Negative. The current price of 0.3 is above the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.33, and below the 200-day MA of 0.61, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 43.11 is Neutral, neither overbought nor oversold. The STOCH value of 63.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:EBR.
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | AU$9.01B | 61.74 | 8.01% | 3.80% | -0.90% | -62.14% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | AU$695.63M | -12.31 | -184.93% | ― | -68.64% | 36.40% | |
45 Neutral | AU$21.97M | -0.42 | -165.13% | ― | 14.85% | -1.74% | |
44 Neutral | AU$222.23M | -2.07 | -169.40% | ― | 3420.67% | 27.04% | |
43 Neutral | AU$3.12M | -1.56 | -1788.57% | ― | -52.22% | 44.79% | |
41 Neutral | AU$19.56M | -1.44 | -180.06% | ― | 74.74% | 4.32% |
* General Sector Average
AU:EBR
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
0.28
-0.98
-77.83%
AU:COH
Cochlear
137.76
-156.54
-53.19%
AU:IPD
Impedimed Limited
0.01
-0.03
-65.85%
AU:UCM
Uscom Limited
0.01
<0.01
9.09%
AU:MX1
Micro-X Ltd.
0.03
-0.05
-67.50%
AU:IMR
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
1.93
0.54
39.35%
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Corporate Events
EBR Systems Completes Conditional Placement to Bolster Wireless Cardiac Pacing Push
Aug 25, 2026
EBR Systems, Inc., a Silicon Valley-based developer of wireless cardiac pacing technologies for heart failure and rhythm disorders, is advancing its proprietary WiSE system, the only wireless endocardial left ventricular pacing platform in clinica...
EBR Systems Seeks ASX Quotation for 92 Million New CDIs
Aug 25, 2026
EBR Systems Inc. has applied for quotation on the ASX of 92,105,270 CHESS depository interests, each representing underlying U.S. securities, with issuance dated August 25, 2026. The move expands the volume of tradable securities on the Australian...
EBR Systems Registers Shares for Equity Incentive Plan to Support Wireless Cardiac Pacing Growth
Aug 25, 2026
EBR Systems, Inc., a Silicon Valley-based medtech company, develops proprietary wireless cardiac pacing technology designed to provide more physiologically effective treatment for cardiac rhythm disease. Its WiSE system delivers endocardial stimul...
EBR Systems ensures commercial continuity as Chief Commercial Officer departs
Aug 20, 2026
EBR Systems has announced that Chief Commercial Officer Erik Strandberg will leave the company in the coming months, with President and CEO John McCutcheon temporarily overseeing the commercial organisation while a search for a successor is undert...
EBR Systems Stockholders Approve All Resolutions at 2026 Special Meeting
Aug 19, 2026
EBR Systems, Inc., a Silicon Valley-based developer of wireless cardiac pacing technology for cardiac rhythm disease, is commercialising its proprietary WiSE system to deliver more physiologically effective left ventricular stimulation for heart f...
EBR Systems accelerates U.S. rollout of wireless heart failure pacing device
Aug 11, 2026
EBR Systems reported strong commercial traction for its WiSE cardiac resynchronization therapy system, surpassing 100 commercial implants and growing to 117 procedures across its pilot launch and limited market release. The company now has 90 trai...
EBR Systems to Spotlight Wireless Cardiac Pacing at Canaccord Growth Conference
Aug 3, 2026
EBR Systems, Inc., developer of the world’s only wireless cardiac pacing device for heart failure, announced that its management team will attend Canaccord Genuity’s 46th Annual Growth Conference in Boston on August 11 and 12, 2026. Pa...
EBR Systems Outlines Q2 2026 Update With Regulatory and Risk Disclosures
Jul 31, 2026
EBR Systems has released a presentation outlining preliminary second-quarter 2026 results and addressing reported complications, positioning the document as general information rather than investment advice. The company emphasises that the materia...
EBR Systems Rules WiSE Implant Complications an Isolated, Manageable Risk
Jul 30, 2026
EBR Systems has completed an internal investigation into serious complications at a single clinical site, where two patients experienced ventricular fibrillation during post-implant echocardiograms following WiSE system implantation, resulting in ...
EBR Systems advances WiSE rollout with growing implants, contracts and funding
Jul 30, 2026
EBR Systems reported further progress in the commercial rollout of its WiSE wireless cardiac pacing system in Q2 2026, completing 46 commercial implants in the quarter and 117 across the pilot and Limited Market Release phases. The company is shif...
EBR Systems to Host Investor Webinar on Q2 Results and Device Speculation
Jul 29, 2026
EBR Systems, Inc., a Silicon Valley-based developer of wireless cardiac pacing technology, is advancing treatment of cardiac rhythm disease with its proprietary WiSE system. The platform enables endocardial stimulation of the left ventricle withou...
EBR Systems Seeks ASX Quotation for Additional CDI Securities
Jul 26, 2026
EBR Systems has lodged a new application with the ASX for quotation of additional CHESS Depository Interests, seeking to list 113,250 CDI securities effective July 1, 2026. The move modestly expands its tradable equity base and may enhance liquidi...
EBR Systems addresses patient incident linked to post-implant imaging
Jul 24, 2026
EBR Systems has addressed online speculation after two patients implanted with its WiSE wireless pacing system at a single site suffered serious complications during post-implant echocardiograms, including one death. The company stated that the ev...
EBR Systems Issues 808,509 Unquoted Options Under Employee Incentive Scheme
Jul 23, 2026
EBR Systems Inc. has notified the market of the issue of 808,509 unquoted options under its employee incentive scheme, with various exercise prices and expiry dates. The options, which are not intended to be quoted on the ASX, underscore the compa...
EBR Systems Streamlines Capital Structure as Warrants and Options Lapse
Jul 23, 2026
EBR Systems Inc. has notified the market of the cessation of certain ASX-listed securities, including 3,639 EBRAH warrants and 55,979 EBRAI options that lapsed on July 1, 2026. The lapse occurred because the conditions attached to these instrument...
EBR Systems Sets Virtual Special Meeting for Global Shareholders
Jul 9, 2026
EBR Systems, developer of a proprietary wireless cardiac pacing system for heart failure patients, has convened a virtual special meeting of stockholders to be held on 19 August 2026 AEST, providing proxy materials and voting instructions to both ...
EBR Systems Director Increases Stake Through Entitlement Offer
Jul 5, 2026
EBR Systems has disclosed a change in director Bronwyn Evans’s interests in the company’s securities, following her participation in a recent entitlement offer. Evans, holding both direct options and an indirect joint holding with Pete...
EBR Systems sets special meeting to ratify capital raisings
Jun 30, 2026
EBR Systems, Inc., a developer of wireless cardiac pacing technology for heart failure patients, is advancing its patented WiSE system, the only wireless endocardial left-ventricular pacing device in clinical use and currently available for sale i...
EBR Systems Seeks ASX Quotation for 114.7 Million New CDIs
Jun 29, 2026
EBR Systems Inc. has lodged an application with the ASX for quotation of 114,699,930 CHESS Depository Interests, with an issue date of June 29, 2026, under its existing EBR code. The new securities, which exclude certain U.S. persons from particip...
EBR Systems Raises A$43.6m as Retail Entitlement Offer Closes
Jun 24, 2026
EBR Systems has completed the retail component of its fully underwritten 1-for-2 pro-rata accelerated non-renounceable entitlement offer, issuing new CHESS Depositary Interests at A$0.38 each to raise about A$10.9 million from retail investors. Co...
EBR Systems Director Evans Boosts Stake with 300,000 CDI Purchase
Jun 18, 2026
EBR Systems has disclosed a change in director Bronwyn Evans’ interests, revealing an on‑market purchase of 300,000 CHESS Depositary Interests (CDIs). The transaction, executed at prices of $0.38 and $0.385 per CDI in two equal tranche...
EBR Systems launches A$150m fully underwritten capital raise
Jun 4, 2026
EBR Systems has launched a fully underwritten A$150 million capital raising, combining an accelerated non-renounceable pro rata entitlement offer and an institutional placement of new CHESS Depositary Interests at A$0.38 each. The offer, open to e...
EBR Systems to Raise Capital via Accelerated Entitlement Offer and Placement
Jun 4, 2026
EBR Systems Inc. has announced a proposed issue of CHESS Depositary Interests on the ASX through an accelerated non-renounceable entitlement offer and a separate placement. The capital raising, which will see hundreds of millions of new securities...
EBR Systems launches capital raising via placement and entitlement offer
Jun 4, 2026
EBR Systems has launched a capital raising that combines a placement of new CHESS Depositary Interests to institutional and sophisticated investors with an accelerated non-renounceable pro-rata entitlement offer to eligible shareholders in Austral...
EBR Systems launches A$150m equity raising to fund WiSE System rollout
Jun 4, 2026
EBR Systems plans to raise A$150 million through a fully underwritten institutional placement and a 1-for-2 pro rata accelerated non-renounceable entitlement offer, issuing about 394.7 million new CDIs at A$0.38 each, a discount to recent trading ...
EBR Systems Seeks ASX Trading Halt Ahead of Capital Raising Announcement
Jun 4, 2026
EBR Systems, Inc., a U.S.-based medtech company listed on the ASX, develops cardiac rhythm management technologies and accesses Australian investors through CHESS Depositary Interests. Its products are aimed at improving treatment options for pati...
CMS Fast-Tracks Medicare Coverage Review for EBR Systems’ WiSE Heart Device
Jun 3, 2026
EBR Systems has secured initiation of a National Coverage Determination review by the U.S. Centers for Medicare Medicaid Services for its WiSE wireless left ventricular pacing system used in cardiac resynchronization therapy. The move follows the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.